Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB

Blood (2015) 126 (23): 2669.

https://doi.org/10.1182/blood.V126.23.2669.2669

Published: 2015

Journal Articles

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Ruth M de Tute, MSc, Jane Shingles, PhD, Andy C. Rawstron, PhD, Roger G Owen, MD

Blood (2014) 124 (21): 3425.

https://doi.org/10.1182/blood.V124.21.3425.3425

Published: 2014

Journal Articles

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Ruth M de Tute, MSc, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Peter W.M. Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 3013.

https://doi.org/10.1182/blood.V122.21.3013.3013

Published: 2013

Journal Articles

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Andy C Rawstron, PhD, Chi Doughty, PhD, Ruth M de Tute, Fiona Bennett, Selina Denman, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Andrew Jack, PhD, MB

Blood (2010) 116 (21): 2002.

https://doi.org/10.1182/blood.V116.21.2002.2002

Published: 2010

Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock

Blood (2009) 114 (22): 3428.

https://doi.org/10.1182/blood.V114.22.3428.3428

Published: 2009

Journal Articles

Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy.

Marwan Kwok, MB, ChB, Andy C. Rawstron, PhD, Abraham Varghese, MB, ChB, MRCP, Peter Hillmen, MB, ChB, PhD

Blood (2009) 114 (22): 540.

https://doi.org/10.1182/blood.V114.22.540.540

Published: 2009

Journal Articles

Defining Complete Response in Multiple Myeloma: Role of the Serum Free Light Chain Assay and Multiparameter Flow Cytometry.

Roger G. Owen, MD, J. Anthony Child, MD, Andy C. Rawstron, Phd, Sue Bell, Phd, Kim Cocks, Phd, Faith E. Davies, MD, Graham H. Jackson, MD, Gareth J. Morgan, MD, PhD, Mark T. Drayson, MD

Blood (2007) 110 (11): 1479.

https://doi.org/10.1182/blood.V110.11.1479.1479

Published: 2007

Journal Articles

Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as “Unmutated” Have the Greatest Clonal Diversity.

Andy C. Rawstron, PhD, James A.L. Fenton, PhD, Marieth Plummer, MSc, Harry O. King, BSc, Fiona L. Bennett, MSc, Andrew S. Jack, PhD, Peter Hillmen, MD

Blood (2006) 108 (11): 30.

https://doi.org/10.1182/blood.V108.11.30.30

Published: 2006

Journal Articles

Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.

Quentin A. Hill, MD, Ruth M. de Tute, MSc, J. Anthony Child, MD, Andy C. Rawstron, PhD, Roger G. Owen, MD

Blood (2006) 108 (11): 3512.

https://doi.org/10.1182/blood.V108.11.3512.3512

Published: 2006

Journal Articles

Rapid and Sensitive Detection of Minimal Plasma Cell Populations Using Six-Colour Flow Cytometry.

Ruth M. de Tute, MSc, Selina J. Denman, BSc, J. Anthony Child, MD, Roger G. Owen, MD, Andy C. Rawstron, PhD

Blood (2006) 108 (11): 3526.

https://doi.org/10.1182/blood.V108.11.3526.3526

Published: 2006

Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD

Blood (2006) 108 (11): 34.

https://doi.org/10.1182/blood.V108.11.34.34

Published: 2006

Journal Articles

Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.

Matthew J. Cullen, MSc, Sharon L. Barrans, PhD, Stephen J. Richards, PhD, Andy C. Rawstron, PhD, Sheila J.M. O’Connor, PhD, Reuben M. Tooze, PhD, Roger G. Owen, MD, Andrew Jack, MD

Blood (2006) 108 (11): 4643.

https://doi.org/10.1182/blood.V108.11.4643.4643

Published: 2006

Journal Articles

Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status.

Fiona L. Bennett, BSc, James A.L. Fenton, DPhil, Sheila J.M. O’Connor, PhD, Peter Hillmen, MD, PhD, Andy C. Rawstron, PhD

Blood (2006) 108 (11): 29.

https://doi.org/10.1182/blood.V108.11.29.29

Published: 2006

Journal Articles

Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features.

Fiona L. Bennett, BSc, Andy C. Rawstron, PhD, Sheila J.M. O’Connor, PhD, Paul A.S. Evans, PhD, Peter Hillmen, MD, PhD

Blood (2006) 108 (11): 2815.

https://doi.org/10.1182/blood.V108.11.2815.2815

Published: 2006

Journal Articles

Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.

Roger G. Owen, MD, Im Fan, MSc, Sheila J.M. O’Connor, Phd, Faith E. Davies, MD, Rebecca A. Rollett, BSc, J. Anthony Child, MD, Andy C. Rawstron, Phd

Blood (2006) 108 (11): 5051.

https://doi.org/10.1182/blood.V108.11.5051.5051

Published: 2006

Journal Articles

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Sheila J. O’Connor, PhD, Kathryn Turner, MSc, Sharon L. Barrans, PhD, Brad Dickinson, MSc, Andy C. Rawstron, PhD, Hazem Sayala, MD, Paul Moreton, MD, Roger G. Owen, MD, Andrew S. Jack, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 2936.

https://doi.org/10.1182/blood.V106.11.2936.2936

Published: 2005

Journal Articles

IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL.

James A.L. Fenton, DPhil, David Gonzalez, PhD, Andy C. Rawstron, PhD, Gareth J. Morgan, MS, BCh, PhD, Andrew S. Jack, MB ChB PhD, Stephen J. Richards, PhD, Peter Hillmen, MB ChB PhD

Blood (2004) 104 (11): 2793.

https://doi.org/10.1182/blood.V104.11.2793.2793

Published: 2004

NARROW

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy.

Defining Complete Response in Multiple Myeloma: Role of the Serum Free Light Chain Assay and Multiparameter Flow Cytometry.

Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as “Unmutated” Have the Greatest Clonal Diversity.

Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.

Rapid and Sensitive Detection of Minimal Plasma Cell Populations Using Six-Colour Flow Cytometry.

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.

Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status.

Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features.

Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only